Skip to main content
. 2025 Aug 12;16:1630311. doi: 10.3389/fimmu.2025.1630311

Figure 5.

Scientific image showing multiple panels related to lung cancer research with high CD8 levels and treatments. Panel A: Survival probability graph comparing patients with high and low CD8. Panel B: Diagram explaining anti-PD-1 injection timeline. Panel C: Images of LLC cells with different Kctd10 expressions. Panel D: Western blot of Kctd10 and Tubulin in LLC cells. Panel E: Percent survival graph comparing different treatment groups. Panel F: Histological images of tumors and bar graph of tumor burden area. Panel G: Staining of Kctd10, β-catenin, and Pdl1 in tumor tissues. Panel H: Immunofluorescence showing DAPI, Kctd10, and CD8a in tissues.

Overexpression of Kctd10 combined with anti-PD-1 therapy effectively suppresses lung tumor colonization. (A) Effect of Kctd10 expression on patient survival in high CD8 expression cohorts. (B) Combined therapeutic strategy for LLC tumors inoculated into C57BL/6 mice. (C, D) Construction and validation of stable LLC cell lines overexpressing Kctd10. (E, F) Effect of Kctd10 and anti-PD-1 therapy on lung tumor size and survival in LLC-bearing mice (n=4/group). (G) IHC analysis of β-catenin and Pd-l1 proteins expression following Kctd10 overexpression and anti-PD-1 treatment. (H) IF analysis of CD8a proteins expression following Kctd10 overexpression and anti-PD-1 treatment. *P < 0.05, **P < 0.01, ***P < 0.001.